Millions of very young children currently excluded from treatment with the drug ivermectin could be safely included in ongoing campaigns against challenging and often neglected tropical diseases such as intestinal worms, scabies and river blindness, according to results from a clinical trial presented today at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH 2025) held in Toronto.
This article was originally published on MedicalXpress.com

